← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 81개
ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.9%임상시험 126상태 ACTIVE
AntibodystaleGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
ADCBiologicstaleBristol-Myers SquibbPhase 1

Revlimid (Revlimid)

Lymphoma; Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#ADC#Phase1#인기#항체약물접합체+4
효능 ORR 90%임상시험 62상태 RECRUITING
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 32.1%임상시험 58상태 DISCONTINUED
CGTBiologicstaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicstaleCRISPR Therapeutics AGPhase 2

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 25%임상시험 53상태 ACTIVE
AntibodystaleGenmabPhase 2

Epcoritamab (Epcoritamab)

Diffuse Large B-Cell Lymphoma; Follicular Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 0%임상시험 50상태 RECRUITING
ADCBiologicEisai Inc.Phase 2

DOC Group B (DOC Group B)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 42상태 RECRUITING
CGTBiologicstaleBristol Myers Squibbvedotin plus bendamustine a…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.5%임상시험 34상태 ACTIVE
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleMarcela V. Maus, M.D.,Ph.D.Phase 2

Emapalumab (Emapalumab)

Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 60%임상시험 29상태 RECRUITING
ADCBiologicstaleCelgenePhase 2

CC-99282 (CC-99282)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 21상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
ADCBiologicstaleNektar TherapeuticsPhase 2

NKTR-255 (NKTR-255)

Multiple Myeloma; Non-Hodgkin Lymphoma · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 4상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

Rituxumab (Rituxumab)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 95%임상시험 4상태 ACTIVE
AntibodyBiologicstaleGenentech, Inc.Phase 2

Bispecific antibody-based combined with CAR-T cell therapy (Bispecific antibody-based combined with CAR-T cell therapy)

B-cell Non-Hodgkin Lymphoma · B-cell Non-Hodgkin Lymphoma

#B-cellNon-HodgkinLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 3상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Bv-AVD-R (Bv-AVD-R)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING
ADCBiologicstaleNational Center for Complementa…Phase 2

MAD CP (MAD CP)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 RECRUITING

1 / 5 페이지

← 이전다음 →